Grant: Project Grant
University of British Columbia
$100,000.00
Mechanism underlying hyporesponsiveness to Interleukin-10 in Type II Diabetes
EF 2016-17
Résumé
In Canada, ~2.5 million people have Type 2 diabetes (T2D) and these numbers are expected to rise due to poor diet choices, insufficient physical activity and our aging population. The pathogenesis of T2D is complex, but chronic production of inflammatory mediators by specialized immune cells called macrophages is a key component. Interleukin-10 (IL10) is a soluble mediator that acts as the body's natural anti-inflammatory agent. We have made the novel discovery that cells from T2D patients are resistant to the anti-inflammatory effect of IL10 and another cytokine called interleukin-6 which can have anti-inflammatory action. We will study how to restore anti-inflammatory responses as a new treatment for T2D.
Programme
Project Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
351785
Name
Mui Alice L
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Mechanism underlying hyporesponsiveness to Interleukin-10 in Type II Diabetes
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Ampk; Biomarker; Inflammation; Macrophage; Ship1 Inositol Phosphatase; Type 2 Diabetes
Abstract
In Canada, ~2.5 million people have Type 2 diabetes (T2D) and these numbers are expected to rise due to poor diet choices, insufficient physical activity and our aging population. The pathogenesis of T2D is complex, but chronic production of inflammatory mediators by specialized immune cells called macrophages is a key component. Interleukin-10 (IL10) is a soluble mediator that acts as the body's natural anti-inflammatory agent. We have made the novel discovery that cells from T2D patients are resistant to the anti-inflammatory effect of IL10 and another cytokine called interleukin-6 which can have anti-inflammatory action. We will study how to restore anti-inflammatory responses as a new treatment for T2D.
Competitiondate
201604
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mui, Alice L; Elliott, Thomas G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
